Transdermal Drug Delivery Systems Market

Market Overview:

The global transdermal drug delivery systems market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.8% during 2023-2028.

The transdermal drug delivery system (TDDS) is an alternative system of delivering drugs through the skin for systemic distribution. It is used as an alternative to oral intravascular, subcutaneous, and transmucosal routes. TDDS supports both chronic and acute diseases as well as cosmetic procedures as it delivers biologically active agents, such as drugs and cosmeceuticals, through the skin. It offers a controlled release of drugs, which reduces the first-pass metabolism effects, lessens the side effects, and improves the efficacy of the dosage by enabling a steady blood drug profile throughout the treatment.

Transdermal Drug Delivery System Market Trends:

The global transdermal drug delivery systems market is primarily driven by the growing instances of chronic disorders that cannot be treated through conventional drug delivery systems, such as oral drugs. Patients with long-term ailments, such as diabetes, are shifting toward self-administration of medicine. As a result, there has been an introduction of adhesive skin patches to administer the daily course of medication without the pain. This has encouraged patients and physicians to prefer pain-free drug delivery systems. Besides this, the wide adoption of third-generation transdermal drug delivery systems like iontophoresis promotes self-reliance in patients since it reduces frequent visits to hospitals and lessens the cumulative treatment costs. Furthermore, technological advancements, such as the inclusion of microneedles, modifications in transdermal patch designs and the incorporation of pressure-sensitive adhesives and permeation enhancers, are providing vast opportunities to manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global transdermal drug delivery systems market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology and application.

Breakup by Technology:

• Electroporation
• Radiofrequency
• Iontophoresis
• Microporation
• Thermal
• Mechanical Arrays
• Ultrasound
• Others
   

Breakup by Application:

• Central Nervous System
• Pain Management
• Cardiovascular
• Hormone
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Acrux Limited, Boehringer Ingelheim International GmbH, Hisamitsu Pharmaceutical Co. Inc., Lavipharm S.A., LEAD CHEMICAL Co. Ltd., Luye Pharma Group, Nutriband Inc. and Viatris Inc.

Report Coverage:

Key Questions Answered in This Report:

• How has the global transdermal drug delivery systems market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global transdermal drug delivery systems market?
• What are the key regional markets?
• What is the breakup of the market based on the technology?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global transdermal drug delivery systems market and who are the key players?
• What is the degree of competition in the industry?